| 发明名称 | Peptide antagonists of the vasopressin-2 receptor | ||
| 摘要 | The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research. | ||
| 申请公布号 | US9631001(B2) | 申请公布日期 | 2017.04.25 |
| 申请号 | US201314427733 | 申请日期 | 2013.09.17 |
| 申请人 | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);UNIVERSITY OF REGENSBURG;UNIVERSITY DE LIEGE | 发明人 | Gilles Nicolas;Servent Denis;Quinton Loïc;Reinfrank Helen;Witzgall Ralph;Mouillac Bernard;Mendre Christiane |
| 分类号 | C07K14/46;A61K38/17;A61K38/00 | 主分类号 | C07K14/46 |
| 代理机构 | Alston & Bird LLP | 代理人 | Alston & Bird LLP |
| 主权项 | 1. A method of inhibiting the vasopressin-2 receptor (V2R) pathway in a subject in need thereof comprising administering a V2R antagonist to the subject, wherein said V2R antagonist comprises a isolated protein, comprising an amino acid sequence which is at least 65% identical to residues 1 to 57 of SEQ ID NO: 1, and which comprises: (i) a motif X1X2X3X4 in positions 15 to 18 of SEQ ID NO: 1, wherein X1 is an asparagine (N), X2 is a glycine (G), X3 and X4 are hydrophobic amino acids or X1 is a methionine (M), X2 and X3 are phenylalanines (F), and X4 is an Isoleucine (I), and (ii) one to three disulfide bonds between two cysteine residues, and wherein said V2R antagonist is administered to the subject in an amount sufficient to inhibit the V2R pathway. | ||
| 地址 | Paris FR | ||